Cbl International Limited shares rise 4.38% premarket after Nurix Therapeutics presents positive clinical data for bexobrutideg.

Cbl International Limited rose 4.38% in premarket trading, with the company's positive clinical data from the ongoing NX-5948-301 study, a Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed or refractory B-cell malignancies. The data include findings from the fully enrolled Phase 1a dose escalation study in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and the ongoing Phase 1a/1b cohorts of patients with Waldenström macroglobulinemia (WM).